Inhibitor Therapeutics, Inc. (INTI)
USD 0.07
(14.55%)
USD 0.07
(14.55%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -3.4 Million USD | -417.53% |
| 2022 | -657.92 Thousand USD | -102.19% |
| 2021 | -325.39 Thousand USD | 69.27% |
| 2020 | -1.05 Million USD | 61.46% |
| 2019 | -2.74 Million USD | 39.8% |
| 2018 | -4.56 Million USD | 10.84% |
| 2017 | -5.11 Million USD | 27.1% |
| 2016 | -7.02 Million USD | -77.8% |
| 2015 | -3.94 Million USD | -0.3% |
| 2014 | -3.93 Million USD | -96.91% |
| 2013 | -1.99 Million USD | -256.68% |
| 2012 | -560.67 Thousand USD | 42.91% |
| 2011 | -982.09 Thousand USD | -135.99% |
| 2010 | -416.15 Thousand USD | 79.88% |
| 2009 | -2.06 Million USD | 17.84% |
| 2008 | -2.51 Million USD | 10.57% |
| 2007 | -2.81 Million USD | -193.37% |
| 2006 | -959.4 Thousand USD | -479.15% |
| 2005 | 253.03 Thousand USD | -3.26% |
| 2004 | 261.55 Thousand USD | 69.09% |
| 2003 | 154.67 Thousand USD | 145.4% |
| 2002 | -340.7 Thousand USD | 74.33% |
| 2001 | -1.32 Million USD | -109.62% |
| 2000 | -633.26 Thousand USD | 65.99% |
| 1999 | -1.86 Million USD | 15.37% |
| 1998 | -2.2 Million USD | -144.44% |
| 1997 | -900 Thousand USD | -550.0% |
| 1996 | 200 Thousand USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -585.15 Thousand USD | 24.48% |
| 2024 Q1 | -774.82 Thousand USD | 39.15% |
| 2023 Q1 | -629.72 Thousand USD | -48.65% |
| 2023 Q3 | -759.52 Thousand USD | -2.3% |
| 2023 FY | -3.4 Million USD | -417.53% |
| 2023 Q4 | -1.27 Million USD | -67.64% |
| 2023 Q2 | -742.46 Thousand USD | -17.9% |
| 2022 FY | -657.92 Thousand USD | -102.19% |
| 2022 Q1 | -93.5 Thousand USD | -225.12% |
| 2022 Q3 | -69.98 Thousand USD | 1.15% |
| 2022 Q2 | -70.8 Thousand USD | 24.27% |
| 2022 Q4 | -423.63 Thousand USD | -505.31% |
| 2021 FY | -325.39 Thousand USD | 69.27% |
| 2021 Q1 | -167.75 Thousand USD | -200.97% |
| 2021 Q3 | -66.24 Thousand USD | -5.77% |
| 2021 Q2 | -62.63 Thousand USD | 62.66% |
| 2021 Q4 | -28.75 Thousand USD | 56.59% |
| 2020 Q3 | -302.77 Thousand USD | 3.89% |
| 2020 Q4 | -55.73 Thousand USD | 81.59% |
| 2020 Q2 | -315.04 Thousand USD | 18.26% |
| 2020 FY | -1.05 Million USD | 61.46% |
| 2020 Q1 | -385.44 Thousand USD | 39.57% |
| 2019 Q3 | -682.92 Thousand USD | -7.46% |
| 2019 Q1 | -791.6 Thousand USD | 40.46% |
| 2019 FY | -2.74 Million USD | 39.8% |
| 2019 Q4 | -637.87 Thousand USD | 6.6% |
| 2019 Q2 | -635.5 Thousand USD | 19.72% |
| 2018 Q4 | -1.32 Million USD | -13.1% |
| 2018 FY | -4.56 Million USD | 10.84% |
| 2018 Q3 | -1.17 Million USD | -32.92% |
| 2018 Q2 | -884.4 Thousand USD | 24.72% |
| 2018 Q1 | -1.17 Million USD | -29.76% |
| 2017 Q4 | -905.35 Thousand USD | -32.91% |
| 2017 FY | -5.11 Million USD | 27.1% |
| 2017 Q1 | -2.81 Million USD | -1.79% |
| 2017 Q3 | -681.16 Thousand USD | 5.32% |
| 2017 Q2 | -719.43 Thousand USD | 74.43% |
| 2016 FY | -7.02 Million USD | -77.8% |
| 2016 Q4 | -2.76 Million USD | -59.35% |
| 2016 Q3 | -1.73 Million USD | -30.38% |
| 2016 Q2 | -1.33 Million USD | -11.35% |
| 2016 Q1 | -1.19 Million USD | -15.61% |
| 2015 Q2 | -791.65 Thousand USD | 14.2% |
| 2015 Q3 | -1.2 Million USD | -51.84% |
| 2015 Q4 | -1.03 Million USD | 14.05% |
| 2015 FY | -3.94 Million USD | -0.3% |
| 2015 Q1 | -922.67 Thousand USD | -2.85% |
| 2014 Q4 | -897.13 Thousand USD | -21.55% |
| 2014 Q2 | -2.11 Million USD | -1031.79% |
| 2014 Q3 | -738.09 Thousand USD | 65.11% |
| 2014 FY | -3.93 Million USD | -96.91% |
| 2014 Q1 | -186.93 Thousand USD | 12.34% |
| 2013 Q3 | -1.29 Million USD | -220.24% |
| 2013 Q4 | -213.24 Thousand USD | 83.5% |
| 2013 Q2 | -403.58 Thousand USD | -345.72% |
| 2013 Q1 | -90.54 Thousand USD | 56.2% |
| 2013 FY | -1.99 Million USD | -256.68% |
| 2012 Q4 | -206.74 Thousand USD | -50.39% |
| 2012 Q3 | -137.46 Thousand USD | -23.37% |
| 2012 Q2 | -111.42 Thousand USD | -6.08% |
| 2012 Q1 | -105.03 Thousand USD | 87.99% |
| 2012 FY | -560.67 Thousand USD | 42.91% |
| 2011 Q4 | -874.66 Thousand USD | -11979.25% |
| 2011 Q3 | 7363.00 USD | 128.57% |
| 2011 Q1 | -89.01 Thousand USD | -109.82% |
| 2011 Q2 | -25.77 Thousand USD | 71.04% |
| 2011 FY | -982.09 Thousand USD | -135.99% |
| 2010 Q1 | -488.11 Thousand USD | 47.02% |
| 2010 FY | -416.15 Thousand USD | 79.88% |
| 2010 Q4 | 906.39 Thousand USD | 336.75% |
| 2010 Q3 | -382.85 Thousand USD | 15.22% |
| 2010 Q2 | -451.57 Thousand USD | 7.49% |
| 2009 FY | -2.06 Million USD | 17.84% |
| 2009 Q4 | -921.25 Thousand USD | -73.24% |
| 2009 Q3 | -531.79 Thousand USD | -297.12% |
| 2009 Q2 | -133.91 Thousand USD | 72.16% |
| 2009 Q1 | -480.97 Thousand USD | 25.21% |
| 2008 FY | -2.51 Million USD | 10.57% |
| 2008 Q2 | -365.06 Thousand USD | 45.93% |
| 2008 Q1 | -675.11 Thousand USD | -64.16% |
| 2008 Q4 | -643.1 Thousand USD | 31.14% |
| 2008 Q3 | -933.93 Thousand USD | -155.83% |
| 2007 FY | -2.81 Million USD | -193.37% |
| 2007 Q3 | -1.3 Million USD | -70.02% |
| 2007 Q2 | -766.76 Thousand USD | -132.88% |
| 2007 Q1 | -329.25 Thousand USD | 25.95% |
| 2007 Q4 | -411.24 Thousand USD | 68.45% |
| 2006 Q4 | -444.64 Thousand USD | -26.35% |
| 2006 Q3 | -351.91 Thousand USD | -2883.92% |
| 2006 FY | -959.4 Thousand USD | -479.15% |
| 2006 Q2 | 12.64 Thousand USD | 107.2% |
| 2006 Q1 | -175.48 Thousand USD | -789.25% |
| 2005 Q2 | 193.57 Thousand USD | 172.4% |
| 2005 Q1 | -267.37 Thousand USD | -153.06% |
| 2005 Q3 | 300.99 Thousand USD | 55.49% |
| 2005 Q4 | 25.46 Thousand USD | -91.54% |
| 2005 FY | 253.03 Thousand USD | -3.26% |
| 2004 Q1 | 121.99 Thousand USD | 55.8% |
| 2004 FY | 261.55 Thousand USD | 69.09% |
| 2004 Q3 | 161.76 Thousand USD | 93.85% |
| 2004 Q4 | -105.65 Thousand USD | -165.31% |
| 2004 Q2 | 83.45 Thousand USD | -31.59% |
| 2003 Q2 | 15.24 Thousand USD | 122.82% |
| 2003 Q1 | -66.79 Thousand USD | 77.95% |
| 2003 Q3 | 127.92 Thousand USD | 739.28% |
| 2003 FY | 154.67 Thousand USD | 145.4% |
| 2003 Q4 | 78.3 Thousand USD | -38.79% |
| 2002 FY | -340.7 Thousand USD | 74.33% |
| 2002 Q3 | 58.44 Thousand USD | 186.9% |
| 2002 Q4 | -302.93 Thousand USD | -618.32% |
| 2002 Q2 | -67.25 Thousand USD | -132.31% |
| 2002 Q1 | -28.95 Thousand USD | 93.51% |
| 2001 Q3 | -340.37 Thousand USD | -135.93% |
| 2001 Q1 | -444.89 Thousand USD | 20.71% |
| 2001 FY | -1.32 Million USD | -109.62% |
| 2001 Q4 | -446.37 Thousand USD | -31.14% |
| 2001 Q2 | -144.27 Thousand USD | 67.57% |
| 2000 FY | -633.26 Thousand USD | 65.99% |
| 2000 Q4 | -561.06 Thousand USD | -143.63% |
| 2000 Q3 | -230.29 Thousand USD | -7756.02% |
| 2000 Q2 | 3008.00 USD | -98.06% |
| 2000 Q1 | 155.08 Thousand USD | 133.58% |
| 1999 Q3 | -300 Thousand USD | 50.0% |
| 1999 FY | -1.86 Million USD | 15.37% |
| 1999 Q2 | -600 Thousand USD | -20.0% |
| 1999 Q4 | -461.9 Thousand USD | -53.97% |
| 1999 Q1 | -500 Thousand USD | 28.57% |
| 1998 Q3 | -600 Thousand USD | 0.0% |
| 1998 Q2 | -600 Thousand USD | -50.0% |
| 1998 Q1 | -400 Thousand USD | 20.0% |
| 1998 FY | -2.2 Million USD | -144.44% |
| 1998 Q4 | -700 Thousand USD | -16.67% |
| 1997 FY | -900 Thousand USD | -550.0% |
| 1997 Q4 | -500 Thousand USD | 28.57% |
| 1997 Q3 | -700 Thousand USD | -1477.49% |
| 1997 Q1 | 50.81 Thousand USD | 0.0% |
| 1997 Q2 | 50.81 Thousand USD | 0.0% |
| 1996 FY | 200 Thousand USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| HST Global, Inc. | -140.9 Thousand USD | -2316.473% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | -395.666% |
| WPD Pharmaceuticals Inc. | -171.5 Thousand USD | -1885.3% |
| CytoDyn Inc. | -18.05 Million USD | 81.144% |
| RVL Pharmaceuticals plc | -58.99 Million USD | 94.228% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| MultiCell Technologies, Inc. | -722.81 USD | -470975.248% |
| ImmunoCellular Therapeutics, Ltd. | -1.81 Million USD | -87.466% |
| Arch Therapeutics, Inc. | -5.04 Million USD | 32.501% |
| THC Farmaceuticals, Inc. | -29.95 Thousand USD | -11268.119% |
| Reve Technologies, Inc. | -181.48 Thousand USD | -1776.177% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| Alpha Cognition Inc. | -9.7 Million USD | 64.917% |
| Northwest Biotherapeutics, Inc. | -55.5 Million USD | 93.866% |
| SQZ Biotechnologies Company | -75.82 Million USD | 95.509% |
| Resverlogix Corp. | -12.74 Million USD | 73.292% |
| Neon Bloom, Inc. | -389.57 Thousand USD | -774.035% |
| VioQuest Pharmaceuticals, Inc. | 9.74 Million USD | 134.95% |
| Sigyn Therapeutics, Inc. | -2.45 Million USD | -38.678% |
| Mesoblast Limited | -84.14 Million USD | 95.954% |
| GB Sciences, Inc. | -1.42 Million USD | -139.701% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | -395.666% |
| Evofem Biosciences, Inc. | -17.84 Million USD | 80.921% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | -6.64 Million USD | 48.782% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Nuo Therapeutics, Inc. | -3.16 Million USD | -7.471% |
| ContraFect Corporation | -56.88 Million USD | 94.015% |
| AXIM Biotechnologies, Inc. | -2.75 Million USD | -23.78% |
| BioStem Technologies, Inc. | -7.77 Million USD | 56.228% |
| LadRx Corporation | -3.82 Million USD | 10.949% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 78.544% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | -204.288% |
| CSL Limited | 3.7 Billion USD | 100.092% |
| Biomind Labs Inc. | -1 Million USD | -237.259% |
| CNBX Pharmaceuticals Inc. | -931.38 Thousand USD | -265.584% |
| Santhera Pharmaceuticals Holding AG | 81.85 Million USD | 104.16% |
| Nascent Biotech, Inc. | -2.22 Million USD | -52.698% |
| Eiger BioPharmaceuticals, Inc. | -71.78 Million USD | 95.257% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | 169.28% |
| GeneThera, Inc. | - USD | Infinity% |
| Emmaus Life Sciences, Inc. | 3.54 Million USD | 196.186% |
| Adynxx, Inc. | - USD | Infinity% |
| Propanc Biopharma, Inc. | -1.53 Million USD | -121.671% |
| Marizyme, Inc. | -34.08 Million USD | 90.011% |
| Nymox Pharmaceutical Corporation | -8.35 Million USD | 59.222% |
| Alseres Pharmaceuticals, Inc. | -564.72 Thousand USD | -502.947% |
| Zenith Capital Corp. | -8.94 Million USD | 61.926% |
| Intellipharmaceutics International Inc. | -2.85 Million USD | -19.452% |
| Halberd Corporation | -75.05 Thousand USD | -4436.947% |
| Genus plc | 6.4 Million USD | 153.203% |
| Pharming Group N.V. | -4.87 Million USD | 30.219% |
| MetaStat, Inc. | - USD | Infinity% |
| Therapeutic Solutions International, Inc. | -1.98 Million USD | -71.408% |
| IMV Inc. | -38.67 Million USD | 91.195% |
| Affymax, Inc. | -15.04 Million USD | 77.37% |
| SYBLEU INC | -149.18 Thousand USD | -2182.463% |
| Enzon Pharmaceuticals, Inc. | -1.04 Million USD | -226.147% |
| Enzolytics Inc. | -2.14 Million USD | -58.46% |
| argenx SE | -425.04 Million USD | 99.199% |
| AVAX Technologies, Inc. | 6.69 Million USD | 150.875% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | -142.867% |
| Burzynski Research Institute, Inc. | -1.33 Million USD | -154.972% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Accustem Sciences Inc. | -3.74 Million USD | 9.114% |
| NDT Pharmaceuticals Inc. | -25.17 Thousand USD | -13427.926% |
| Cell Source, Inc. | -4.32 Million USD | 21.278% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | -483.06 Thousand USD | -604.874% |
| Q BioMed Inc. | -3.44 Million USD | 1.179% |
| Rasna Therapeutics, Inc. | -4.23 Million USD | 19.664% |
| Capstone Therapeutics Corp. | -1.25 Million USD | -171.097% |
| Mosaic ImmunoEngineering Inc. | -2.62 Million USD | -29.589% |
| PsyBio Therapeutics Corp. | -4.55 Million USD | 25.243% |
| American Oriental Bioengineering, Inc. | -54.97 Million USD | 93.806% |
| Provectus Biopharmaceuticals, Inc. | -2.9 Million USD | -17.362% |
| Rebus Holdings, Inc. | -664 Thousand USD | -412.798% |
| Helix BioMedix, Inc. | -984.05 Thousand USD | -246.016% |
| Skye Bioscience, Inc. | -13.67 Million USD | 75.095% |
| GlobeStar Therapeutics Corporation | -1.86 Million USD | -82.634% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | -69.845% |
| ONE Bio Corp. | 13.68 Million USD | 124.887% |
| Curative Biotechnology, Inc. | -1.93 Million USD | -76.186% |
| Wesana Health Holdings Inc. | -1.12 Million USD | -202.69% |
| Agentix Corp. | -1.37 Million USD | -148.22% |
| Endonovo Therapeutics, Inc. | -2.91 Million USD | -16.631% |
| RespireRx Pharmaceuticals Inc. | -1.57 Million USD | -115.593% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -19445.256% |
| Kadimastem Ltd | -3.04 Million USD | -11.997% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Institute of Biomedical Research Corp. | -261.72 Thousand USD | -1200.971% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | -719.531% |
| NovAccess Global Inc. | -2.46 Million USD | -38.034% |
| Itoco Inc. | -919.14 Thousand USD | -270.453% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NanoSphere Health Sciences Inc. | -220.07 Thousand USD | -1447.169% |
| Qrons Inc. | -643.67 Thousand USD | -428.989% |
| Mobile Lads Corp. | -554.55 Thousand USD | -514.008% |
| Genscript Biotech Corporation | -415.79 Million USD | 99.181% |
| International Stem Cell Corporation | -663 Thousand USD | -413.571% |
| Bioxytran, Inc. | -3.82 Million USD | 10.868% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -6368.425% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -20.34 Thousand USD | -16640.31% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -36.26 Million USD | 90.611% |
| Adhera Therapeutics, Inc. | -1.61 Million USD | -110.444% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -735.83 Thousand USD | -362.737% |
| Innovation Pharmaceuticals Inc. | -3.11 Million USD | -9.45% |
| Neutra Corp. | -229.48 Thousand USD | -1383.741% |
| Windtree Therapeutics, Inc. | -17.53 Million USD | 80.586% |
| PureTech Health plc | -146.19 Million USD | 97.671% |
| Coeptis Therapeutics, Inc. | -21.49 Million USD | 84.156% |
| IXICO plc | -1.43 Million USD | -136.951% |
| IntelGenx Technologies Corp. | -9.49 Million USD | 64.124% |
| Gelesis Holdings, Inc. | -121.8 Million USD | 97.205% |
| CSL Limited | 3.81 Billion USD | 100.089% |
| Cellectis S.A. | -108.85 Million USD | 96.872% |